|
🐜
|
The STRONG(kids) nutritional screening tool in hospitalized children: a validation study.
9 auth.
K. Huysentruyt,
P. Alliet,
L. Muyshont,
R. Rossignol,
T. Devreker,
P. Bontems,
...
J. Dejonckheere,
Y. Vandenplas,
J. De Schepper
|
6 |
2013 |
6
🐜
|
|
🐬
|
Accuracy of Nutritional Screening Tools in Assessing the Risk of Undernutrition in Hospitalized Children
K. Huysentruyt,
T. Devreker,
J. Dejonckheere,
J. De Schepper,
Y. Vandenplas,
F. Cools
|
5 |
2015 |
5
🐬
|
|
🐬
|
Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine
E. Kalso,
K. Simpson,
R. Slappendel,
J. Dejonckheere,
U. Richarz
|
5 |
2007 |
5
🐬
|
|
🐜
|
Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate
8 auth.
J. Buitelaar,
J. Kooij,
J. Ramos-Quiroga,
J. Dejonckheere,
M. Casas,
J. V. van Oene,
...
B. Schäuble,
G. Trott
|
5 |
2011 |
5
🐜
|
|
🐜
|
Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial
8 auth.
J. Kooij,
M. Rösler,
A. Philipsen,
S. Wächter,
J. Dejonckheere,
A. van der Kolk,
...
M. van Agthoven,
B. Schäuble
|
5 |
2013 |
5
🐜
|
|
🐜
|
Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate
8 auth.
J. Buitelaar,
M. Casas,
A. Philipsen,
J. Kooij,
J. Ramos-Quiroga,
J. Dejonckheere,
...
J. V. van Oene,
B. Schäuble
|
5 |
2011 |
5
🐜
|
|
🐜
|
Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study
10 auth.
M. Casas,
M. Rösler,
J. S. Sandra Kooij,
Y. Ginsberg,
J. Ramos-Quiroga,
Steffen Heger,
...
J. Berwaerts,
J. Dejonckheere,
E. Van der Vorst,
B. Schäuble
|
5 |
2013 |
5
🐜
|
|
🐬
|
Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
J. Buitelaar,
E. Sobanski,
R. Stieglitz,
J. Dejonckheere,
S. Waechter,
B. Schäuble
|
4 |
2012 |
4
🐬
|
